Evidence map›Paper›PMID 35210795›Full record

ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2022

Risk Factors Analysis and Management of Cardiometabolic-Based Chronic Disease in Low- and Middle-Income Countries.

Chaitanya Dutt, Joao Eduardo Nunes Salles, Shashank Joshi, Tiny Nair, Subhankar Chowdhury, Ambrish Mithal, Viswanathan Mohan, Ravi Kasliwal, Satyawan Sharma, Jan Tijssen and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Global trends in hypertension prevalence, awareness, treatment, and control.Current opinion in nephrology and hypertension · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 11 institutions in 3 countries.

Chaitanya DuttResearch and Development, Torrent Pharmaceuticals Ltd, Ahmedabad, Gujarat, India.
Joao Eduardo Nunes SallesDiscipline of Endocrinology, Medical Sciences of Santa Casa de São Paulo, São Paulo, Brazil.
Shashank JoshiDepartment of Endocrinology, Lilavati Hospital, Mumbai, Maharashtra, India.
Tiny NairDepartment of Cardiology, PRS Hospital, Thiruvananthapuram, Kerala, India.
Subhankar ChowdhuryDepartment of Endocrinology, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India.
Ambrish MithalDepartment of Endocrinology & Diabetes, Max Healthcare, New Delhi, India.
Viswanathan MohanMadras Diabetes Research Foundation, Chennai, Tamil Nadu, India.ORCID 0000-0001-5038-6210
Ravi KasliwalMedanta- The Medicity, Gurgaon, Haryana, India.
Satyawan SharmaDepartment of Cardiology, Bombay Hospital and Medical Research Center, Mumbai, Maharashtra, India.
Jan TijssenAcademic Medical Center - University of Amsterdam, Amsterdam, the Netherlands.
Nikhil TandonDepartment of Endocrinology, All India Institute of Medical Sciences, New Delhi, India.
All India Institute of Medical Sciences · INAmsterdam UMC Location University of Amsterdam · NLBombay Hospital · INFaculdade de Ciências Médicas da Santa Casa de São Paulo · BRInstitute of Post Graduate Medical Education and Research · INLilavati Hospital & Research Centre · INMadras Diabetes Research Foundation · INMax Healthcare · INMedanta The Medicity · INParas Hospitals · INTorrent Pharma (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidemic of obesity or adiposity-based chronic diseases presents a significant challenge with the rising prevalence of morbidities and mortality due to atherosclerotic cardiovascular diseases (ASCVD), especially in low- and middle-income countries (LMIC). The underlying pathophysiology of metabolic inflexibility is a common thread linking insulin resistance to cardiometabolic-based chronic disease (CMBCD), including dysglycemia, hypertension, and dyslipidemia progressing to downstream ASCVD events. The complex CMBCD paradigm in the LMIC population within the socio-economic and cultural context highlights considerable heterogeneity of disease predisposition, clinical patterns, and socio-medical needs. This review intends to summarize the current knowledge of CMBCD. We describe recently established or emerging trends for managing risk factors, assessment tools for evaluating ASCVD risk, and various pharmacological and non-pharmacological measures particularly relevant for LMICs. A CMBCD model positions insulin resistance and β-cell dysfunction at the summit of the disease spectrum may improve outcomes at a lower cost in LMICs. Despite identifying multiple pathophysiologic disturbances constituting CMBCD, a large percentage of the patient at risk for ASCVD remains undefined. Targeting dysglycemia, dyslipidemia, and hypertension using antihypertensive, statins, anti-glycemic, and antiplatelet agents has reduced the incidence of ASCVD. Thus, primordial prevention targeting pathophysiological changes that cause abnormalities in adiposity and primary prevention by detecting and managing risk factors remains the foundation for CMBCD management. Therefore, targeting pathways that address mitochondrial dysfunction would exert a beneficial effect on metabolic inflexibility that may potentially correct insulin resistance, β cell dysfunction and, consequently, would be therapeutically effective across the entire continuum of CMBCD.

Indexed as

apolipoprotein Bdiabetes mellitusdyslipidemia hypertensioninsulin resistancemitochondrial modulatornon-high-density lipoprotein-cholesteroltriglycerides

Identifiers

PMID35210795
PMCPMC8858768
OpenAlexW4212834633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.